The purging efficacy of positive selection of autologous CD34
Summary:
The purging efficacy of positive selection of autologous CD34
þ PBSC with a clinical scale method of magneticactivated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34 þ cells postselection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34 þ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19 þ cell and CD20 þ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34 þ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 Â 10 9 /l neutrophils of 10 days (range 8-13) and 20 Â 10 9 /l platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy. þ selection; magnetic-activated cell sorting system; autologous PBSCT; phase II study High-dose chemotherapy followed by autologous stem cell transplantation has been established as a standard therapy for the non-Hodgkin's lymphoma (NHL) patients with sensitive relapse, and this treatment strategy has also been widely used for the treatment for NHL with poorprognosis. [1] [2] [3] [4] The biggest concern using this approach is the possibility of reinfusing contaminating NHL cells, which may contribute to relapses post transplant. 5, 6 Therefore, purging techniques selectively removing the tumor cells without compromising the hematopoietic reconstitution capacity of the graft might be important to reduce the relapse rate after high-dose chemotherapy. A more recently used purging method is positive selection of CD34 þ cells. By positive CD34 þ cell selection, the heterogeneity of antigen expression on tumor cells does not play a role and positive CD34 þ cell selection can be used for purging for almost every tumor entity, as long as the target tumor cells to be purged do not express the CD34 þ antigen. The most recently described method for positive selection of CD34 þ cells, which allows the clinical isolation of CD34 þ to a very high purity is magnetic-activated cell sorting (MACS). 7, 8 In this study, we report the results of a clinical trial in which CD34
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þ cells isolated using a large clinical scale device, named CliniMACS, were infused into NHL patients to provide hematopoietic autograft support following high-dose chemotherapy. The primary objective of the study was to evaluate the safety of infusion of the selected CD34 þ cells as assessed by the time to hematopoietic reconstitution and the incidence of adverse events. The secondary objectives were to evaluate the performance of the clinical device as measured by assessment of purity, recovery and viability of the CD34 þ cell product as well as long-term engraftment, immune-reconstitution and production of human anti-mouse antibodies (HAMA). Furthermore, the tumor cell deletion efficacy by CD34 þ cell selection was assessed by the real-time PCR method, utilizing the gene rearrangement clonality of immunoglubulin heavy chain (IgH), as well as the CD19 and CD20 positivities of the selected product.
Patients and methods
This was a multicenter, single arm feasibility study to evaluate the purging efficacy of positive selection of autologous mobilized CD34
þ PBSCs and the safety of CliniMACS for patients with NHL from 13 institutions in Japan. The study schema is illustrated in Figure 1 . Patients were eligible if they had histologically proven B-cell NHL with BM infiltration at diagnosis or prior to PBSC mobilization, were aged 20-64 years, had an ECOG performance status of 0-1, no severe organ dysfunction (pulmonary, PaO 2 X60 mmHg; hematopoietic, neutrophils X1.5 Â 10 9 /l, Hb X9 g/dl and platelets X75 Â 10 9 /l; hepatic, total birilubin o2 mg/dl; renal, serum creatinine o2 mg/dl; cardiac, ejection fraction X50%) and no previous viral infections (hepatitis B or C or human immunodeficiency virus). Patients were not eligible if they received prior auto/allo stem cell transplantation or had active primary cancer in the other organ, or any serious concomitant disease such as severe infection, active rheumatoid arthritis, SLE, bronchial asthma, poorlycontrolled diabetes mellitus and active gastroduodenal ulcer. Patients were also excluded if they had a psychiatric disease or a history of myocardial infarction or poorlycontrolled arrhythmias. This study was carried out according to the principles set out in the Declaration of Helsinki 1975, and the study protocol and informed-consent forms were approved by the institutional review board in each participating institution before study activation. All patients gave written informed consent before registration.
Peripheral stem cell mobilization and collection
The mobilization of hematopoietic progenitor cells was initiated according to the standard chemotherapeutic regimen at each treating institution, followed by G-CSF (400 mg/m 2 /day; filgrastim, Kirin Brewery Co. Ltd, Tokyo, Japan).
The first leukapheresis took place according to each treating institution's decision, usually on the first day post-nadir, when the WBC was^2.0 Â 10 9 /l or when the peripheral blood CD34 þ count was^20 Â 10 6 /l. Further leukaphereses (one or two, if needed) were then carried out on consecutive days. Leukaphereses were performed according to standard practice at each treating institution.
In principle, the products of each of the (first one or two) leukaphereses individually underwent CD34 þ cell selection using the CliniMACS. The last was retained, unselected, as the 'back-up' product.
Fluorescence-activated cell sorting (FACS) analysis of CD34 þ cell numbers before and after selection was carried out at a central laboratory and locally at each treating institution. The central laboratory results were used to assess device performance, in terms of the purity and recovery of the CD34 þ cell population. The institutional analyses were used to make clinical decisions about the future treatment of patients. There was no attempt to 
CD34
þ cell selection CD34 þ cell selection was performed immediately after the leukapheresis product had been collected. The leukapheresis product was transferred to a 600 ml transfer pack (Baxter Healthcare Corporation, Fenwal Division, Deerfield, IL, USA) and brought to a standard volume of 95 ml by centrifugation and removal of excess plasma or by the addition of phosphate-buffered saline (PBS) containing 0.5% human serum albumin and 1 mM EDTA. It was then incubated for 30 min at room temperature with 7.5 ml of murine anti-CD34 antibody (AC101) conjugated to irondextran microbeads (AmCell). The product was then washed twice in PBS containing 0.5% human serum albumin and 1 mM EDTA to remove excess antibody reagent.
The CliniMACS was operated according to the manufacturer's instructions. The tubing set, including separation columns and a microaggregate blood transfusion filter (Pall Biomedical Incorporated, Fajardo, Puerto Rico), was affixed to the CliniMACS system. Under microprocessor control, the tubing set was flushed with PBS containing 0.5% human serum albumin and 1 mM EDTA to remove air bubbles from the separation columns. The 600 ml transfer pack containing the antibody-labeled cells was then attached to the microaggregate blood filter and hung on the CliniMACS system. CD34 þ cell selection was carried out, again under direct microprocessor control. The CD34 þ cell selection was concluded in approximately 30 min and the CD34 þ cells were eluted into a cell collection bag attached to the tubing set. The total volume of the selected cells was approximately 40-45 ml, which, after aseptic collection of samples for analysis, was sent for cryopreservation. All products were cryopreserved according to the standard practice at each treating institution.
Central laboratory CD34
þ cell analysis and assessment of system performance
Immediately after CD34
þ cell selection, fresh samples were sent to the central laboratory. FACS analysis with those fresh samples performed at the central laboratory by ProCOUNT Progenitor Cell Enumeration kit (Becton Dickinson) was used to determine the percentage of CD34 þ cells and was used to assess device performance in terms of the purity and recovery of the CD34 þ population. Briefly, cells in each fraction were stained with CD34 Reagent (Nucleic acid dye/PE-conjugated anti-CD34 Ab/PerCP-conjugated anti-CD45 Ab) incubating in TruCount tubes at room temperature for 15 min. Then, erythrocytes in each fraction were lysed and left at rest with lysis agent at room temperature for 15 min. After that, the percentage of CD34 þ cells in all cells was analyzed by flow cytometry.
The percentage of CD34 þ cells was calculated by the total number of CD34 þ events with low side scatter over the total events in the CD45-FITC (fluorescein isothiocyanate) vs side scatter gate. Following a similar calculation with the control sample, the control value was then subtracted from this value.
Having determined the number of CD34 þ cells in the leukapheresis products, the percentage purity of selected CD34 þ cells was calculated as purity ð%Þ ¼ total number of CD34 þ cells after selection total number of cells after selection Â100
The percentage recovery of selected CD34 þ cells was calculated as recovery ð%Þ ¼ total number of CD34 þ cells after selection total number of CD34 þ cells before selection Â100
Performance of the CliniMACS system was also assessed by cell viability (trypan blue exclusion) before and after cell selection. This assessment was performed at the local laboratories.
Detection of contaminating tumor cells
In this clinical trial, patients with B-cell-type NHL were included and the tumor cells in PBSC samples (minimal residual tumor; MRT) were identified by the real-time PCR method, utilizing the gene rearrangement clonality of IgH.
First, DNA was extracted from the bone marrow (BM) or diseased tissues, and its monoclonality was confirmed. The gene coding for IgH variable region was amplified by the PCR method using the consensus primers, and applied to agarose electrophoresis. When the gene amplification was detected, the clonality was judged to be confirmed. Subsequently, the gene sequence of the IgH variable region was analyzed, to provide the patient-specific primer for determination.
Secondly, the quantity of IgH gene was determined by real-time PCR method using the patient-specific primers. The DNA extracted from the samples before and after cell selection was used as sample material, and the DNA used for clonality detection was diluted and used as the standard sample for DNA calibration curve. The PCR were processed with fluorescent probe and patient-specific primers on the template of sample material or standard sample, and a calibration curve for the DNA concentration (dilution rate of the standard sample) and PCR cycles was provided by detecting and analyzing the fluorescence intensity, to determine the concentration of rearrangement gene in the DNA sample (dilution rate of the standard sample). The detection sensitivity was the concentration (dilution rate) at which gene amplification was confirmed on the agarose electrophoresis after the patient-specific PCR, in the serial dilutions of the standard sample for the DNA calibration curve, and thus, the one-order lower concentration was defined as the detection limit.
As the surface markers of B-cell NHL, the percentages of CD19 þ or CD20 þ cells in both before-and afterseparation fractions were examined by FACS analysis.
Briefly, cells were stained with PE (phycoerythrin)-conjugated anti-CD19 Ab and FITC-conjugated anti-CD20 Ab incubating on ice for 30 min. Then, erythrocytes in each fraction were lysed and left at rest with lysis agent at room temperature for 15 min. After that, the percentage of CD19 þ or CD20 þ cells in mononuclear cells was analyzed by flow cytometry.
High-dose chemotherapy regimen and transplantation procedure
Only patients who got more than 2 Â 10 6 /kg CD34 þ cells in selected products as well as more than 1 Â 10 6 /kg of CD34 þ cells in back-up leukapheresis product could proceed to the high-dose chemotherapy protocol. Otherwise, the patient was withdrawn from the study and treated according to the discretion of the investigator. High-dose chemotherapy regimen, called MCEC, described previously, was used as pre-transplant conditioning therapy. Red cell transfusion as well as platelet transfusion, and antibiotic, antifungal, and antiviral therapy were administered according to standard practice at each treating institution.
Administration of filgrastim, 300 mg/m 2 /day d.i.v, began 24 h after the selected cell infusion and continued until neutrophil engraftment (AGC X5 Â 10 9 /l) had occurred. Blood samples were taken every day until hematopoietic reconstitution was confirmed (defined as an unsupported platelet count of X20 Â 10 9 /l for 3 consecutive days and an absolute neutrophil count of^0.5 Â 10 9 /l). Samples were also taken at 30, 60 and 90 days post transplantation blood samples for routine biochemistry and to assess hematological and immune status and the presence of HAMA.
Immune status was assessed by FACS analysis of CD4 þ and CD8 þ lymphocyte subsets at the central laboratory. HAMA to mouse IgG before and after CD34 þ cell infusion were also evaluated by a solid-phase radioimmunoassay at the central laboratory.
Statistical analysis
The CliniMACS system performance and therapeutic efficacy were evaluated as follows: Overall objective tumor response was evaluated based on the standard response criteria for NHL, reported by Cheson et al.
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Results
Between October 1999 and November 2001, 51 patients were recruited into the study from 13 institutions in Japan. The disposition of the patients is summarized in Figure 2 . Of the 51 patients who were recruited into the study, 48 provided leukapheresis products for selection and three patients were withdrawn from the study prior to CD34 þ cell selection, because of poor CD34 þ cell mobilization. Among the 48 patients, 29 were leukapheresed once and 19 were leukapheresed twice for CD34 þ cell selection. Isolation of CD34 þ cells was performed with 67 leukapheresis products from 48 patients and a total of 67 samples were sent to the central laboratory for analysis. However, six post-selection samples could not be analyzed for CD34 þ cell purity and recovery rate due to technical and logistical problems (delay of analysis for 2-3 days and analysis with frozen samples, other than fresh samples). Of the 48 patients, 41 patients proceeded to treatment with high-dose chemotherapy. Seven patients did not proceed to CD34 þ cell transplantation, because isolated CD34 þ cell did not meet the minimal requirement (2 Â 10 6 /kg) in six patients and change of treatment occurred in one patient (Rituximab therapy). The characteristics of the 41 patients who proceeded to CD34 þ cell transplantation were summarized in Table 1 .
Isolation of CD34 þ cells
In all, 61 samples were evaluable for CD34 þ cell separation performance. Before selection, the median number of cells per product was 151. ), with the median purity being 93.3% (range 32.6-99.3%), which gave a median of 2.79 Â 10 6 (0.1-330.6 Â 10 6 ) CD34 þ cells/kg per patient, representing a median recovery of 72.2% (range 20.5-309.8%). Among the 61 selections, nine selections from eight cases gave over 100% yield (100.4-309.8%), and four selections from three cases gave less than 30% yield (20.8-28.7%). System performance data are presented graphically in Figure 3 . The median cell viability before and after selection was 100% (range 90.5-100%) and 100% (range 97.0-100%), respectively.
Performance of contaminating tumor cell depletion
Among 67 samples from 48 patients, 20 samples from 13 patients could be analyzed for MRT and 63 samples from 47 patients could be analyzed for CD19 and CD20 positivity. The performances of tumor cell depletion are shown in Since MRT was measured by RT-PCR with the produced primer, the sensitivity was different for each of these measurements in order to produce the primer of each patient. The sensitivity range was between 10 À2 and 10 À4 in detectable cases (13 cases, 20 samples). These samples were below sensitivity after CD34 þ cell selection in 7/13 cases (10/20 samples), including two cases (four samples) which were below sensitivity for measurements before and after CD34 þ cell selection (data not shown).
Malfunction and problems with CliniMACS
Three device malfunctions from 67 selection runs were reported, two cases of liquid leakage from tube and one case of tube link. Since all these malfunctions occurred at priming time, they had no influence on the CD34 þ cell selection in all cases. These were prototype devices and resolution measures have been identified and introduced to prevent recurrence.
Hematopoietic reconstitution after selected CD34
þ cell transplantation All of the 41 patients who received high-dose chemotherapy received selected products only. Among the 41 patients, 40 patients could be evaluable for hematopoietic reconstitution. One patient was not evaluable because of disease progression and was treated with cytotoxic agents before hematopoietic reconstitution. The median number of transplanted CD34 þ cells of the 41 patients was 5.45 Â 10 6 /kg (range 2.42-33.80). As summarized in Table 3 , the median time (range) to neutrophil recovery (AGC X0.5 Â 10 9 /l) was 10 days (8-13), with median (range) time to unsupported platelet recovery (Plt X20 Â 10 9 /l) being 14 days (10-34). Lymphoid cell recovery after selected cell transplantation is summarized in Figure 4 . Before high-dose chemotherapy, median (range) number of CD3 þ cells was 3150.0/ml (1312-7280), and dropped to 2262.0/ml (544-6783) at 1 month after transplantation, and recovered to 4298.5/ml (764-12951) at 2 months and 3582.0/ml (1553-7762) at 3 months after transplantation. While CD8 þ cells showed the same recovery pattern as CD3 þ cells, recovery of CD4 þ cells remained poor even after 3 months post selected cell transplantation.
Adverse events
There were no serious adverse events reported as directly related to the infusion of selected products. The adverse event profile was typical of a patient population undergoing high-dose cytotoxic chemotherapy with autologous stem cell support and filgrastim (eg alopecia, gastrointestinal disorders, hepatic disorders and bone pain etc). There were no reports suggesting any significant hypersensitivity reactions or reactions to the iron-dextran in the antibody conjugate.
There were two deaths reported during the study. Both patients experienced severe G-I tract toxicities soon after the administration of high-dose chemotherapeutic agents, which resulted in severe enterocolitis and progressed to systemic septicemia. Although experiencing either platelet or neutrophil recovery (patient no. 1: AGC 0.44 Â 10 9 /l, Plt 6 Â 10 9 /l; patient no. 2: AGC 1.54 Â 10 9 /l, Plt 20 Â 10 9 /l), the patients died of septicemia 10 days and 12 days after infusion of selected cells. Neither of the two deaths was reported as being associated with selection procedures or infusion of selected cells.
Since CD4 þ cell recovery was poor after selected cell transplantation shown in Figure 4 , the risk of opportunistic infection was evaluated. In all, 14 patients experienced several infections within 90 days after selected cell transplantation, including viral infections with CMV (seven cases), herpes simplex (two cases), and herpes zoster (one case).
All patients completed 30, 60 and 90 day follow-ups after infusion, during which time their hematological and immune status was monitored, as was HAMA production. There were no reports of late engraftment failure defined either as the need for additional blood transfusions or use of the 'back-up' leukapheresis product after hematopoietic reconstitution had occurred. One patient was reactive for HAMA 4 months after selected cell transplantation and remained positive until 22 months, but became negative at Clinical follow-up after high-dose chemotherapy with CD34 þ cell transplantation
Objective response rate, overall and disease-free survival were analysed in 41 patients who underwent high-dose chemotherapy with selected cell transplantation. Among the 41 patients, 36 patients were evaluable for an objective response. After high-dose chemotherapy, 14 patients who were CR before transplantation remained CR (38.9%), 11 patients became CR/CRu (30.6%), three patients became PR (8.3%), five patients became SD (13.9%) and three patients had disease progression (8.3%). The KaplanMeier analysis of the overall survival and the progressionfree survival of the 41 patients were shown in Figure 5 . The 2-year progression-free survival and overall survival rate were 37.7% (95% CI: 22.7-52.8%) and 68.3% (95% CI: 54.0-82.5%), respectively.
Discussion
The present study is the first report of the clinical use of the large-scale cell selection system (CliniMACS) in Japan. Among 61 selections, nine selections from eight cases gave over 100% yield (100.4-309.8%), and four selections from three cases gave less than 30% yield (20.8-28.7%). The recovery of CD34 þ cells is included in the errors in some calculations (CD34 þ measurement by FACS, cell number count and medium volume) before and after CD34 þ cell selection, that is, unavoidable margin of error. These over 100% recovery samples that were calculated as the CD34 þ measurements either underestimated the CD34 þ cell content before CD34 þ cell selection or overestimated CD34 þ cell content after CD34 þ cell selection. On the other hand, these low yield samples might be a calculation error for CD34 þ measurements as the over 100% yield cases; additionally these include two samples which treated over capacity (CD34 þ 46 Â 10 8 cells) in one CD34 þ cell selection (data not shown).
Among 48 patients who underwent CD34 þ cell selection, six patients could not proceed to CD34 þ cell transplantation because of low CD34 þ cell recovery. The main reason for this low recovery may be poor stem cell mobilization, as well as poor stem cell harvest, because the total CD34 þ cell number before selection was quite low (0.12-2.6 Â 10 6 /kg). In this clinical trial, the number of leukaphereses for CD34 þ cell selection was limited to twice. Development of optimal stem cell mobilization method as well as additional stem cell collection before CD34 þ cell selection would be needed to get a sufficient number of CD34 þ cells for definite and safe stem cell transplantation.
The primary objective of the present study was the evaluation of the safety of infusion of the selected CD34 þ cells as assessed by the time to hematopoietic reconstitution and the incidence of adverse events. When infused after high-dose chemotherapy, the selected cells resulted in rapid engraftment in the present study (Table 3) , which is quite similar to published data using the same pre-conditioning regimen (MCEC) and autologous unselected stem cell transplantation. 9 Using the CliniMACS, the same favorable hematopoietic reconstitution after CD34 þ cell transplantation has been reported, 11 and the engraftment times obtained with the CliniMACS system compare well to those seen with unselected cells and CD34 þ cells selected using other technologies. 12, 13 A unique aspect of the CliniMACS system is that the antibody conjugate, once bound to the CD34 þ cells, is not removed and is then infused into the patient after high-dose chemotherapy, which might cause an allergic reaction. In the present study, no hyperallergic adverse events were seen after selected cell infusion, but HAMA production was observed in one patient. During the observation period, the patient was treated with anti-CD20 monoclonal antibody (Rituximab) with no adverse reaction.
The data from the present study also suggest that infusion of CD34 þ cells selected via the CliniMACS system results in durable long-term engraftment, because none of the patients required the infusion of back-up stem cell product. The effects on immunological reconstitution following CD34 þ selected cells have been of great concern for opportunistic fungal infections and various viral infections. In the present study, the pattern of early recovery and 'overshoot' of CD8 þ cells compared with CD4 þ cells within 2 months of transplant was observed that has been previously described in patients receiving BM or peripheral blood progenitor cells. 14, 15 During the 90-day follow-up after infusion of selected cells in the present study, several viral infections, especially CMV infections, were reported. Fortunately, all of the CMV infections reported in the present study were CMV antigemia (pp65) only, and were successfully treated with ganciclovir. Since such infections have been reported following infusion of CD34 þ cells selected using other systems, [16] [17] [18] more intensive supportive care, especially for the prevention of viral infection, would be required for the management of CD34 þ cell selected transplant. A principal application of CD34 þ cell selection is the reduction in tumor cell contamination of autografts prior to infusion to the patient. In the present study, 20 samples from 13 patients could be analyzed for patient-specific gene rearrangement clonality of IgH. Using this quite specific and sensitive method, the median depletion rate of MRT Overall survival Progression-free survival Figure 5 Kaplan-Meier analysis of the overall survival and the progression-free survival after CD34 þ cell transplant (41 patients).
CD34 þ selection for NHL Y Imai et al was 2.53 log (range 1.52-4.78), which was comparable to the experimental report, 19 indicating that selection of CD34 þ cells by CliniMACS would be useful for eliminating considerable amounts of contaminating lymphoma cells in a large clinical setting. Furthermore, the present study may be the first report to demonstrate that patient-specific MRT could be successfully depleted by CliniMACS in a large-scale clinical setting in NHL patients. This favorable depletion efficacy was also confirmed by the present results that CD19
þ cells, as well as CD20 þ cells, could be eliminated by 2.46 log (range 0.74-3.64) and 2.32 log (range 0.40-4.01), respectively.
In NHL patients, it was indicated that residual lymphoma cells in BM may contribute to relapse and the NHL patients with bcl-2-positive BM had markedly and significantly worse relapse-free survival than those who had undetectable bcl-2 rearrangement. 20 Although studies using ex vivo purged stem cell transplantation have demonstrated better disease-free and/or overall survival compared with conventional chemotherapy-treated, historical control groups in phase II setting, there has been no clear evidence of benefit through tumor cell purging, because of the lack of confirm data from direct comparisons between purged vs unpurged stem cells in phase III setting. 21, 22 In the present study, 13 out of 48 patients undergoing stem cell harvest could be evaluated for MRT in the stem cell product. Among the 13 patients, 11 patients proceeded to high-dose chemotherapy with CD34 þ selected cell transplantation, and seven patients had disease progression after high-dose chemotherapy (data not shown). Since the number of patients analyzed here was too small and these patients were quite heterogeneous in histology and disease status, it was difficult to draw any conclusion that CD34 þ cell selection with CliniMACS had any impact on survival on the patients whose MRT were consistently eliminated by 2.5 log level.
In conclusion, high purity as well as high recovery rate obtained in this study indicated that CliniMACS is quite an efficient and reliable device for CD34 þ selection for largescale clinical use. Since the positive selection as sole modality for purging appears to be not sufficient to obtain an MRT-negative stem cells, further investigation, such as in vivo and ex vivo purging system utilizing Rituximab, 23, 24 is warranted.
